Development, opportunities, and challenges of siRNA nucleic acid drugs by Bowen Xiao, Shaopeng Wang, Yu Pan, Wenjun Zhi, Chensheng Gu, Tao Guo, Jiaqi Zhai, Chenxu Li, Yong Q. Chen, Rong Wang

“…They have reached the market for administration to patients after more than 20 years of development. The US Food and Drug Administration has approved six siRNA drugs in recent years: patisiran, givosiran, lumasiran, vutrisiran, inclisiran, and nedosiran. siRNA drugs are based on the post-transcriptional gene regulation mechanism of RNA interference. …”
Get full text

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases by Siyu Lou, Zhiwei Cui, Yingyong Ou, Junyou Chen, Linmei Zhou, Ruizhen Zhao, Chengyu Zhu, Li Wang, Zhu Wu, Fan Zou

“…As such, this study aimed to comprehensively evaluate real-world adverse drug events (ADEs) linked to paliperidone palmitate by employing data mining techniques on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. …”
Get full text

Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized tria... by Yuanyuan Chen, Yan Chen, Hong Zhen, Danhua Lou

“…Recently, the Food and Drug Administration (FDA) has approved tumor treating fields (TTF) for the treatment of glioblastoma. …”
Get full text

Radiopharmaceuticals and their applications in medicine by Siqi Zhang, Xingkai Wang, Xin Gao, Xueyao Chen, Linger Li, Guoqing Li, Can Liu, Yuan Miao, Rui Wang, Kuan Hu

“…Radiopharmaceutical therapy, which directly causes systematic and irreparable damage to targeted cells, has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies. As the Food and Drug Administration (FDA) approvals of [177Lu]Lu-DOTA-TATE, [177Lu]Lu-PSMA-617 and their complementary diagnostic agents, namely, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-PSMA-11, targeted radiopharmaceutical-based theranostics (radiotheranostics) are being increasingly implemented in clinical practice in oncology, which lead to a new era of radiopharmaceuticals. …”
Get full text

Computer-guided identification of novel inhibitors of apoptosis-signaling kinase 1 from Spondia mombim bioactive compounds against colorectal cancer by Olusola Olalekan Elekofehinti, Hannah Oluwaseun Popoola, Adedotun Olayemi Oluwatuyi, Opeyemi Iwaloye, Moses Orimoloye Akinjiyan, Oluwamodupe Cecilia, Frank Abimbola Ogundolie, Olalekan Isaac Olatunde, Oussama Abchir, Samir Chtita, Joao Batista Texeira Rocha

Get full text

Private, public, and bottled drinking water: Shared contaminant-mixture exposures and effects challenge by Paul M. Bradley, Kristin M. Romanok, Kelly L. Smalling, Stephanie E. Gordon, Bradley J. Huffman, Katie Paul Friedman, Daniel L. Villeneuve, Brett R. Blackwell, Suzanne C. Fitzpatrick, Michael J. Focazio, Elizabeth Medlock-Kakaley, Shannon M. Meppelink, Ana Navas–Acien, Anne E. Nigra, Molly L. Schreiner

Get full text

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database by Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo

“…This study aimed to evaluate the adverse events (AEs) of IDH inhibitors based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database. …”
Get full text

Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data by Luyang Su, Ren Xu, Yanan Ren, Shixia Zhao, Weilan Liu, Zeqing Du

“…This study aimed to evaluate the adverse events (AEs) associated with MPA in by analyzing real-world data from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS). …”
Get full text

Dual targeting of breast cancer by chitosan/poly lactic-co-glycolic acid nanodelivery systems: Surface activation with folic acid/aptamers, and co-encapsulated with Sorafenib and q... by Asghar Narmani, Saeid Ganji, Maryam Amirishoar, Fatemeh Hajikarimi, Aynaz Mazandarani, Mahya Karimi, Ali Mohammadinejad, Azin Azadpour, Roghayyeh Jahedi, Elham Assadpour, Seid Mahdi Jafari

Get full text

Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database by Yuwei Liu, Yuwei Liu, Xu Zhao, Xu Zhao, Xinrui Wang, Xinrui Wang, Qiang Zhou, Qiang Zhou

“…Currently, there is no Food and Drug Administration (FDA) approved pharmacotherapy for liver fibrosis. …”
Get full text

Impact of warning pictorials and size on perceived effectiveness of cigar warning labels in a nationally representative between-subjects experiment by James F Thrasher, Tara L Queen, Jennifer Cornacchione Ross, Sarah D Kowitt, Leah M Ranney, Adam O Goldstein, Chineme Enyioha, Desmond Jenson, Paschal Sheeran, Sonia A Clark, Kristen L Jarman, Michelle Z Yang

“…Our findings provide important insights for the US Food and Drug Administration and international regulatory agencies in designing new HWLs for cigars that can more effectively communicate smoking risks, address misinformation and potentially reduce cigar smoking.…”
Get full text

E-Cigarette Use and Use of Evidence-Based Smoking Cessation Methods Among American Indian Cigarette Smokers: A Cross-Sectional Analysis by Ashley L. Comiford, DrPH, Dorothy A. Rhoades, MD, MPH, Justin D. Dvorak, PhD, Kai Ding, PhD, Noah Collins, Alexandra L. Blair, Mark P. Doescher, MD, MSPH

“…Although the U.S. Food and Drug Administration–approved products and evidence-based methods exist for smoking cessation, people who smoke might use E-cigarettes as cessation aids. …”
Get full text

Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLU... by Brian Hiestand, Phillip Levy, W Frank Peacock, Brigitte M Baumann, Richard M Nowak, Amy Hsu, Joseph Varon, Chad M Cannon, David M Cline, Pierre Borczuk, Abhinav Chandra, Deborah B Diercks, Preeti Jois, Brian Kaminski, Jon W Schrock

“…Objective To compare the efficacy of Food and Drug Administration recommended dosing of nicardipine versus labetalol for the management of hypertensive patients with signs and/or symptoms (S/S) suggestive of end-organ damage (EOD).Design Secondary analysis of the multicentre prospective, randomised CLUE trial.Setting 13 academic emergency departments in the USA.Participants Eligible patients had two systolic blood pressure (SBP) measures ≥180 mm Hg at least 10 min apart, no contraindications to nicardipine or labetalol and predefined S/S suggestive of EOD on arrival.Interventions Medications were administered by continuous infusion (nicardipine) or repeat intravenous bolus (labetalol) for a study period of 30 min or until a specified target SBP ±20 mm Hg was achieved.Primary outcome measure Percentage of participants achieving a predefined target SBP range (TR) defined as an SBP within ±20 mm Hg as established by the treating physician.Results Of the 141 eligible patients, 49.6% received nicardipine, 51.7% were women and 81.6% were black. …”
Get full text

Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinica... by Jens Juul Holst, Tina Vilsbøll, Claus Thorn Ekstrøm, Helene Benveniste, Nora D Volkow, Anders Fink-Jensen, Gitte M Knudsen, Mette Kruse Klausen, Tugba Kuzey, Julie Niemann Pedersen, Signe Keller Justesen, Line Rasmussen, Ulla B Knorr, Graeme Mason, George Koob

“…Treatment options are sparse, with only three Food and Drug Administration (FDA)-approved pharmacotherapies. …”
Get full text

Geographically widespread and novel hemotropic mycoplasmas and bartonellae in Mexican free-tailed bats and sympatric North American bat species by Daniel J. Becker, Kristin E. Dyer, Lauren R. Lock, Beckett L. Olbrys, Shawn A. Pladas, Anushka A. Sukhadia, Bret Demory, Juliana Maria Nunes Batista, Micaela Pineda, Nancy B. Simmons, Amanda M. Adams, Winifred F. Frick, M. Teague O'Mara, Dmitriy V. Volokhov

Get full text

Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer by Saisai Tian, Mengting Xu, Xiangxin Geng, Jiansong Fang, Hanchen Xu, Xinying Xue, Hongmei Hu, Qing Zhang, Dianping Yu, Mengmeng Guo, Hongwei Zhang, Jinyuan Lu, Chengyang Guo, Qun Wang, Sanhong Liu, Weidong Zhang

“…In this study, a network‐based computational framework called multi‐network algorithm‐driven drug repositioning targeting ICP (Mnet‐DRI) is developed to accurately repurpose novel ICIs from ≈3000 Food and Drug Administration‐approved or investigational drugs. …”
Get full text

Deep learning-based aberration compensation improves contrast and resolution in fluorescence microscopy by Min Guo, Yicong Wu, Chad M. Hobson, Yijun Su, Shuhao Qian, Eric Krueger, Ryan Christensen, Grant Kroeschell, Johnny Bui, Matthew Chaw, Lixia Zhang, Jiamin Liu, Xuekai Hou, Xiaofei Han, Zhiye Lu, Xuefei Ma, Alexander Zhovmer, Christian Combs, Mark Moyle, Eviatar Yemini, Huafeng Liu, Zhiyi Liu, Alexandre Benedetto, Patrick La Riviere, Daniel Colón-Ramos, Hari Shroff

Get full text

Bringing MDMA-assisted therapy for PTSD to traditional healthcare systems: tending to set and setting by Dimitri Perivoliotis, Dimitri Perivoliotis, Kayla Knopp, Kayla Knopp, Shannon Remick, Allie Kaigle, Allie Kaigle, Christopher S. Stauffer, Christopher S. Stauffer, Chandra Khalifian, Chandra Khalifian, Tamara R. Wachsman, Bettye E. Chargin, Andrew W. Bismark, Andrew W. Bismark, Al Alam, Al Alam, Leslie Morland, Leslie Morland, Leslie Morland

“…MDMA-assisted therapy (MDMA-AT) for PTSD is a promising intervention currently being evaluated in numerous studies worldwide, including investigation for potential Food and Drug Administration (FDA) approval in the United States. …”
Get full text

Relieving Sore Throat Formula Exerts a Therapeutic Effect on Pharyngitis through Immunoregulation and NF-κB Pathway by Yushi Ding, Suyun Yu, Zhonghong Wei, Rui Deng, Peng Chen, Yifan Sun, Qi Jia, Xiaoman Li, Yuanyuan Wu, Wenxing Chen, Kurt S. Zanker, Aiyun Wang, Yin Lu

“…Relieving Sore Throat Formula (RSTF) is a formula approved by the China Food and Drug Administration and has been used for the treatment of pharyngitis in clinic for many years. …”
Get full text

The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review by Goren S, Kidwai N, Aronow WS, Lanier GM

“…Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. …”
Get full text